Eli Lilly and Company (LLY) Shares Sold by Meiji Yasuda Life Insurance Co

Meiji Yasuda Life Insurance Co decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 12.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,307 shares of the company’s stock after selling 2,500 shares during the quarter. Meiji Yasuda Life Insurance Co’s holdings in Eli Lilly and were worth $1,424,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its position in Eli Lilly and by 3.3% during the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after purchasing an additional 2,181,701 shares during the last quarter. BlackRock Inc. boosted its position in Eli Lilly and by 2,628.5% during the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after purchasing an additional 59,978,664 shares during the last quarter. State Street Corp boosted its position in Eli Lilly and by 1.6% during the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock valued at $3,563,230,000 after purchasing an additional 651,424 shares during the last quarter. Geode Capital Management LLC boosted its position in Eli Lilly and by 8.4% during the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after purchasing an additional 708,597 shares during the last quarter. Finally, Janus Capital Management LLC boosted its position in Eli Lilly and by 2.8% during the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after purchasing an additional 237,619 shares during the last quarter. Institutional investors and hedge funds own 75.66% of the company’s stock.

A number of analysts recently issued reports on LLY shares. TheStreet raised Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Citigroup Inc. reissued a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a research report on Tuesday, July 4th. Berenberg Bank reissued a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a research report on Thursday, July 27th. Deutsche Bank AG reissued a “buy” rating and set a $91.00 price objective (up previously from $90.00) on shares of Eli Lilly and in a research report on Monday, July 17th. Finally, Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a research report on Monday, July 17th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $89.76.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.com-unik.info/2017/10/30/eli-lilly-and-company-lly-shares-sold-by-meiji-yasuda-life-insurance-co.html.

Eli Lilly and Company (NYSE:LLY) opened at 83.86 on Monday. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $89.09. The firm has a market cap of $88.47 billion, a PE ratio of 36.29 and a beta of 0.34. The company’s 50 day moving average price is $84.90 and its 200 day moving average price is $82.27.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.72%. The business had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same period last year, the business posted $0.88 EPS. Eli Lilly and’s revenue was up 9.0% on a year-over-year basis. Analysts predict that Eli Lilly and Company will post $4.20 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.48%. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $81.06, for a total value of $14,590,800.00. Following the completion of the sale, the insider now directly owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 770,000 shares of company stock valued at $64,669,850 over the last quarter. 0.20% of the stock is currently owned by company insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit